Professional Documents
Culture Documents
F : M ratio Disease
9 : 1 Sjorgen
Hashimoto
Graves
Systemic lupus erythematosus
2-3 : 1 Myasthenia gravis
Multiple sclerosis
Rheumatoid arthritis
-1 : 1 Autoimmune hemolytic anemia
Idiopathic thrombocytopenic purpura
Type I diabetes
Vitiligo
Pemphigus
< 1 : 1 Goodpasture
Ankylosing spondylitis
Lockshin MD. Sex differences in autoimmune disease. Lupus 2006 ; 15: 753-756.
NEW PARADIGM
OLD
PARADIGM
ONE OR BOTH
POSITIVE NEGATIVE
POSITIVE
Interpret result in
Clarify with: Likelihood of lupus-like clinical context
DNA (More common with
#
condition low Clarify with DNA3
Homogenous ANA patterns) Further testing (More common
ENA (Often speckled ANA) probably not indicated* with Homogenous
ANA patterns)
Reeves .G.E.M, Update on the immunology, diagnosis and management of systemic lupus erythematosus.
Internal medicine journal 2004;34:338-347
Drugs implicated in the development of DILE
Definite Probable Possible Recent case
reports
Hydralazine Sulphasalazine Antibiotics Infliximab
Procainamide Anticonvulsants Non-steroidal Etanercept
anti
inflammatory
agents
Isoniazid Anti-thyroid Antihypertensi Interleukin-2
ves
Methyldopa Statins Lithium Zafirlukast
Quinidine Terbinafine Interferons Clobazam
Minocycline Penicillamine Gold salts Tocainide
Chlorpromazine Fluoroucacil agents Lisinopril
Hydrochlorthiazide Bupropion
Vasoo S. Drug-induced lupus: anm update. Lupus 2006 ; 15 :757-761.
Potential model for autoimmunity
development
Response to
Healthy,
Environmental
No AutoAbs
Exposure
Primordial
Autoimmne
Genetically
Response
Susceptible
Individual
Healthy
Cross
Autoimmunity Reaction (s)
Organ/ Epitope
Spreading to
Tissue Pathogenic
Damage AutoAbs
Harley JB, Harley ITW, Guthridge JM and James JA. The curiously suspicious: a role for Epstein-Barr virus in Lupus
LOOKING FOR ENVIRONMENTAL FACTORS
AT THE RIGHT TIME
MULTIPLE
ENVIRONMENTAL
EXPOSURES
Genetically DISEASE
susceptible
individual
Clinical disease
Early life infectious exposure may Threshold
programme a plastic immune system
Edwards CJ and Cooper C. Early environmental exposure and the development of lupus. Lupus 2006 ; 15 :
814-819.
Genetic influence
Environmental factors
Arbuckle MR. Development of Auto antibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med
2003;349:1526-33
Steps in Pathogenesis of SLE
1. Genetic factors/immune
dysfunction
2. Environmental/endogenous
trigger
3. Inflammation
4. Development of
Autoimmune
5. Accelerated of Antigen
6. Tissue Damage
7. Clinical Disease
Autoimmune pathogenesis paradigm. APC, antigen-
presenting cell; MHC, major histocompability complex
AUTOIMMUNE AUTOIMMUNITY EVOLVING
*DIATHESIS* WITHOUT DISEASE SPECTRUM OF
AUTOIMMUNE
DISEASE
Genetic Risk Factors :
Autoreactive
- MHC
Lymphocytes
- Other
Autoreactive Autoreactive
Lymphocytes Lymphocytes
Modulating and Perpetuating Factors acting at multiple levels: e.g. UV radiation, hormones, drugs,
Reeves G.E.M. Update on the immunology, diagnosis and management of systemic lupus erythematosus. Internal Medicine Journal
R. Rose Noel, Mackay R. Ian. The Autoimmune Disease Fourth
edition. 2006
Autoantibodies Precede
Disease by Years
Some AutoAb
before Dx: 80%
Sel cerna
SLE Arthritis/Arthralgia
90%
18%
Skin
Lung 50-58%
38% Kidney
Hematology 50%
Heart Vasculitis
50%
48%
Trigger/Eksaserbation
Procainamid
Drugs: Hidralazin UV radiance
Metildopa
CPZ
(320-400 nm)
Abortion Infection
SLE
Pregnancy Surgery
The 1997 Revised Criteria for
the Classification of SLE
(MD SOAP BRAIN)
1. Malar rash
2. Discoid rash
3. Serositis
a. Pericarditis
b. Pleuritis
4. Oral ulcer
5. Arthritis
6. Photosensitivity
The 1997 Revised Criteria for
the Classification of SLE
7. Blood / Hematologic disorder
a. Hemolytic anemia OR
b. Leukopenia (< 4000/ ml) OR
c. Lymphopenia (<1500/ ml) OR
d. Thrombocytopenia (<100.000)
8. Renal disorder
a. Persistent Proteinuria (>0.5 gr/d)
b. Cellular cast or any tipe
9. ANA
10. Immunologic disorder
a. Anti ds DNA OR
b. Anti Sm OR
c. Antiphospholipid ab
11. Neurological disorder
Mechanism
of Sedimentation Immune Complex
Oral Ulcers
Photosensitivity
Discoid Lupus
Discoid Lupus
Small Vessel
Vasculitis
Erythematous Rash
Heart be involved in
SLE
Pericarditis
Myocarditis
Vasculitis
Secondary atherosclerotic coronary artery
disease & myocardial infarction
Secondary hypertensive disease
Valvular disease
Lung be involved in SLE
Pleuritis
Acute lupus pneumonitis
Chronic intestial lung disease
Pulmonary hypertension
Pulmonary embolism
Neuropsychiatric syndromes
associated with SLE
Central nervous system Peripheral nervous system
Aseptic meningitis Guillain-Barr syndrome (acute
Cerebrovascular disease inflammatory
Demyelinating syndrome polyradiculoneuropathy)
Headache Autonomic disorder
Movement disorders (chorea) Mononeuropathy
Myelopathy (single/multiplex)
Seizures and Seizure Myasthenia gravis
disorders Cranial neuropathy
Acute confusional state Plexopathy
Anxiety disorder Polyneuropathy
Cognitive dysfunction
Mood disorders
Psychosis
Active SLE
Secondary to drug
Sepsis associated with SLE
Clinical Monitoring2
ESR, CRP
ANA
95% positive screening test for SLE
3 - 5% negative
5 - 25% population positive
Clinical Monitoring3
Other Antibodies
Anti Ro (SS-A)
Anti La (SS-B)
Anti Sm
Anti RNP
ACA
ANCA
Maybe helpful in confirming
a diagnosis (not be used in
monitoring)
Clinical Monitoring4
Anti DNA antibodies
- ~ active SLE
- Monitoring patients response to theraphy
- Associated organ disease activity renal
disease
- Complement levels: C3C4, CH50
Global measures of disease
activity
LACC (Lupus Activity Criteria Count)
SLAM (The systemic Lupus Activity Measure) clinical
features
BILAG (The british Isles Lupus Activity Group) intent
to treat approach
SLEDAI (The systemic Lupus Disease Activity Index)
- prognostic studies severity (Toronto 1985) / clinical &
laboratory
ECLAM (European Consensus Lupus Activity
Measurement) ~ SLEDAI
Global measures of
damage SLE
Diet
Weather
General
Management
Smoking
Induction
Maintenance
Prednison Cyclo MM
Prednison AZT MM
Principles of therapy
1. Remission
2. Organ/ Renal
Survival
3. Patient Survival
4. Complication/
Comorbid
5. Quality of Life
(Cost)
LES MEDICATION
Anti malaria
Hydrockcycloroquin
Cloroquin
Cortikosteroide
Prednisone
Metilprednosolone
Immunosupresif
Azathioprine
MMF
Cyclophospamide
Plasmapheresis
New Treatments for systemic lupus
erythematosus
B-cell anergy
LJP 394: abetimus
B-cell depletion
Anti-CD20: rituximab
Anti-CD22: epratuzumab
Other techniques
Immunoadsorption
AntiC5a
T cell vaccination
chain transfection
Peptide therapies: edratide targeting antiDNA
idiotypes
Wallace J Daniel & Hahn Hannahs Bevra : Dubois lupus Erythematosus, Seventh Edition,
Lippincot Williams & Wilkins 2007
B. Immunosuppressive effects*
1. Lymphopenia**
2. Inhibition of signal transduction events critical for T-cell
activation
3. Inhibition of IL2 synthesis and signaling
4. Downregulation of cell surface molecules important for full T-
cell activation and function
5. Inhibition of antigen-presenting cell function. Depletion of
plasmacytoid dendritic cells and production of interferon-alpha
6. Deviation of immune responses towards a Th2-type cytokine
formation
7. Induction of T-cell apoptosis
Wallace J Daniel & Hahn Hannahs Bevra : Dubois lupus Erythematosus, Seventh Edition, Lippincot
Williams & Wilkins 2007
High-Dose Corticosteroid
Therapy
1. Severe lupus nephritis
2. CNS lupus with severe
manifestations
3. Autoimmune thrombocytopenia
(<30000/mm3)
4. Autoimunehemolytic anemia
5. Acute pneumonitis
1 gr/IV 3 hari berturut-turut
Journal Article
PROTOCOL FOR USING MONTHLY
IV CYCLOPHOSPHAMIDE1
SUPPORT
CARE TREATMEN
T
MONITORING
Use of GC During Stress
Patients on chronic GC therapy should be given
supplemental GC during the stress of surgery or
moderate severe illness
Minor Stress
25 mg of hydrocortisone (or its equivalent) should
be given daily for 1-3 days during minor sheers
Moderate/Severe Stress
50-75 mg hydrocortisone for 1-3 days
Severe Stress
100-150 mg for hydrocortisone
Usual Regimens of Systemic Glucocorticoid Therapy in SLE*
GC Regimen Representative Indications
Pulse GC (PGC): 250 mg Life or organ-threatening complications
PDNeq /d x 1-5 days. Typically 0.5- (i.e.,RPGN, myelopathy, severe acute
1 g MP/d IV x 1-3 d, monthly as confusional state, alveolar hemorrhage,
indicated. Usually with oral GC (30- vasculitis, optic neuritis)**
60 mg PDNeq/d) HDGC-refactory Disease
DPGN or severe FPGN
Very High Dose GC (VHDGC): > 100 Life or organ-threatening complications (as
mg PD Neq/d, IV/PO (Start with for PGC)**
divided doses)
DPGN or severe FPGN (for less than 6-8
High Dose GC (HDGC): >30 mg and weeks)
100 mg PDNeq/d, IV/PO Thrombocytopenia/hemolytic anemia
Acute lupus pneumonitis; Lupus crisis
(max 2 gr)
6 month 0,25 05 gr.
(Pisoni Cn, Karim Y, Cuadrado MJ. Lupus
2005, 14, s9 s11.)
Euro Lupus Maintain Low dose Cyclo (CTX) :
6 X 500 mg pulses fortnightly
MMF or Azathioprine
PRD was started at 0,8 mg /Kg BW/day
p.o. and tapered to reach 10 mg / day at
approximately six months and then taper
then maintained
Complete remission :
- Urinary protein exertion < 0,3 gr / 24
- Normal urinary sediment
- Normal serum albumin
- Improve or stable renal function
(Cahn TM. Lupus nephritis : Induction
therapy. Lupus 2005. 14, s27-s32
Euro Lupus Maintain Low dose Cyclo (CTX) :
6 X 500 mg pulses fortnightly
MMF or Azathioprine
PRD was started at 0,8 mg /Kg BW/day
p.o. and tapered to reach 10 mg / day at
approximately six months and then taper
then maintained
Complete remission :
- Urinary protein exertion < 0,3 gr / 24
- Normal urinary sediment
- Normal serum albumin
- Improve or stable renal function
(Cahn TM. Lupus nephritis : Induction
therapy. Lupus 2005. 14, s27-s32
New Treatment in SLE
(cell surface molecules)
Treatment Mode of action Status
Anti CD20 (Rituximab) B cell depletion Phase II/III trial in
patients SLE is
ongoing
Anti CD22 Modulation of B cell Safe in phase I. Phase
(Epratuzumab) signaling II it is on going
AE Monitoring for
Muscle Psychiatric Proximal muscle weakness
Symptoms of depression,
psychosis
Eye Visual changes,
Other risk factors
(NSAIDs, co-morbidities)
Suggested Monitoring and Preventive-
Therapeutic Interventions for Selected GC
Adverse Effects (AE)*1
AE Monitoring for
HPA-axis suppression Symptoms of adrenal
insufficiency during
significant stress ( illness,
or surgery)
Osteoporosis BMD at baseline and q12
months thereafter if
bisphosphonates are not
given .
Osteocronosis Unexplained joint /bone
pain. (Perform MRI to
detect early GION if plain
radiography not revealing)
Suggested Monitoring and Preventive-
Therapeutic Interventions for Selected GC
Adverse Effects (AE)*2
AE Monitoring for
Cardio-vascular Lipidemia
Hypertension
Hyperglycemia Obesity
NL
DPL
50-60% Urinalisis
Ureum/Cr/GD
APS Nepritis lupus(NL)
KEHAMILAN ACL/LA
SSA/SSB
Hipertensi C3/C4
Preleklamsi Antids DNA
24 jam Urin
Abortus Sc (+) Sc (-) protein
PARTUS
Treatment :
Systemic GC : 1-1.5 kg PDN/ Kg/day
Clinical Response : (1-8 weeks)
Guidelines for Use Oral Contraceptives in Women
with Systemic Lupus Erythematosus
1. Inactive or stable/moderate disease
2. No history of venous or arterial thrombosis
3. IgGaPL <40, IgMaPL <40, IgAaPL <50, no circulating
lupus anticoagulant (Unknown if presence of low-to-
moderate titer of aPL in the absence of a previous
thrombosis is contraindication)
4. Nonsmoker
5. Normotensive
6. For combined pill, use lowest dose of ethinyl estradiol
(30-35 g)
7. Patient without migraine headaches
8. Can add low-dose aspirin therapy to hormone regimen
if there is concern about risk factors
Dobois Lupus Erythematosus, 1-2-3 Wallece J. Daniel, 1997
Lupus Eritematosus Sistemik (LES)
Nanang Sukmana
Subbagian Alergi - Imunologi Klinik
Bag. Ilmu Penyakit Dalam FKUI / RSCM - Jakarta
Lupus eritematosus sistemik (LES)
Sal cerna
LES Artritis/Artralgia
90%
18%
Kulit
Paru 50-58%
38% Ginjal
Hematologi 50%
Jantung Vaskulitis
50%
48%
Faktor
pencetus/eksaserbasi
Procainamid
Hidralazin Sinar UV
Obat : Metildopa (320-400 nm)
CPZ
Keguguran Infeksi
LES
Tindakan
Kehamilan pembedahan
Sinar matahari
Kelelahan
Diet
Cuaca
Penatalaksanaan
Umum
Merokok
Kontrasepsi oral Stres dan
trauma fisik
4 / 11 ARA 3 / 11
WHO LLD
LES
Kerusakan
Organ
Vaskulitis Ginjal Hematologi Jantung Paru SSP
Anemia hemolitik Efusi Metilpred
Prednison
Dosis Prednison : Dosis Prednison
60-100 mg/hari 1-1,5 mg/kgbb/hari
2 mg/kg/hari
15-40 mg/hari
(Hari-minggu) 60-80mg 100-120 mg + drainage 3-5 hari oral
(4-6 minggu / 8-12 minggu) L.pneumonitis pred
Trombositopeni Dosis Prednison 48-80 mg/hari
Prednison :1 mg/kgBB 1-1,5 mg/kg/hari
Azatiopin : 2,5 mg/kgBB
Dosis Prednison 5-7 hari
1-2 mg/kgbb/hari (4-6 minggu)
Siklophospamid : 0.5 1 gr/m2 60-80 mg/hari
(4 minggu)
LES Inaktif
NL
DPL
50-60% Urinalisis
Ureum/Cr/GD
APS Nepritis lupus(NL)
KEHAMILAN ACL/LA
SSA/SSB
Hipertensi C3/C4
Preleklamsi Antids DNA
24 jam Urin
Abortus Sc (+) Sc (-) protein
PARTUS
Wallace J Daniel & Hahn Hannahs Bevra : Dubois lupus Erythematosus, Seventh Edition,
Lippincot Williams & Wilkins 2007
B. Immunosuppressive effects*
1. Lymphopenia**
2. Inhibition of signal transduction events critical for
T-cell activation
3. Inhibition of IL2 synthesis and signaling
4. Downregulation of cell surface molecules important
for full T-cell activation and function
5. Inhibition of antigen-presenting cell function.
Depletion of plasmacytoid dendritic cells and
production of interferon-alpha
6. Deviation of immune responses towards a Th2-type
cytokine formation
7. Induction of T-cell apoptosis
Wallace J Daniel & Hahn Hannahs Bevra : Dubois lupus Erythematosus, Seventh Edition, Lippincot
Usual Regimens of Systemic Glucocorticoid Therapy in SLE*
GC Regimen Representative Indications
Pulse GC (PGC): 250 mg Life or organ-threatening complications
PDNeq /d x 1-5 days. Typically 0.5- (i.e.,RPGN, myelopathy, severe acute
1 g MP/d IV x 1-3 d, monthly as confusional state, alveolar hemorrhage,
indicated. Usually with oral GC (30- vasculitis, optic neuritis)**
60 mg PDNeq/d) HDGC-refactory Disease
DPGN or severe FPGN
Treatment :
Systemic GC : 1-1.5 kg PDN/ Kg/day
Clinical Response : (1-8 weeks)
Recommended Therapy for Lupus Nephritis
Disease severity Induction Therapy Maintenance Therapy
PRD was started at 0,8 mg /Kg BW/day p.o. and tapered to reach 10 mg /
day at approximately six months and then taper then maintined
Complete remission :
- Urinary protein exretion < 0,3 gr / 24 hours
- Normal urinary sediment
- Normal serum albumin
- Improve or stable renal function
(Cahn TM. Lupus nephritis : Induction therapy. Lupus 2005.
14, s27-s32
Outcome measure in the induction and
maintenance treatment of lupus nephritis
Induction treatment
Remission and response
Decrease in proteinuria to < 1g/day(or < 0.8 g/day in
cases of lupus nephritis that were diagnosed in the past
6 months) with normal serum albumin concentrations;
inactive urine sediment ; improved or stable renal
function
Boumpas T Dimitrios, Sidropoulus Prodromos, Bertsias George Bertsias, Optimum therapeutic approaches for lupus
nephritis: what therapy and for whom?, Nature publishing group, 2005
Outcome measure in the induction and
maintenance treatment of lupus
nephritis
Treatment failure
Persistent proteinuria of 3g/day or any degree of
proteinuria with serum albumin <3g/day or progressive
renal impairment (i.e. a reproducible 33% or > 0.3
mg/dl increase from baseline serum creatinine, whichever
is greater) after the first 6-12 months of treatment
Boumpas T Dimitrios, Sidropoulus Prodromos, Bertsias George Bertsias, Optimum therapeutic approaches for lupus
nephritis: what therapy and for whom?, Nature publishing group, 2005
Beberapa jenis obat untuk berbagai kondisi pada Lupus1
Class Generic name Uses
Non-steroidal anti- Ibuprofen Relief of Inflammatory
inflammatory drugs pains in muscles, joints,
serosae etc
Naproxen
Indomethacin
Celecoxib COX-2 inhibitors (2 less
Gr toxicity)
Rofecoxib
Antimalarias Hydroxychloroquine Autoimmune-related
fatigue, arthropathy
and rash; limited
evidence of efficacy for
sicca, thrombophilia and
pain
Reeves. G.E.M. Update on the immunology, diagnosis and management of systemic lupus
erythematosus. Internal Medicine Journal 2004;34:338-347.
Beberapa jenis obat untuk berbagai kondisi pada Lupus2
Class Generic name Uses
Corticosteroids Prednisone Serositis, cytopenias,
major organ Involvement;
low-dose transient use for
refractory
musculocutaneous features
Potent Azathioprine All potent
Immunomodulators Methotrexate immunomodulators have the
Cyclosporine following uses: Severe
Cyclophosphamide organ involvement or
Leflunomide cytopenia, steroid-sparing
Mycophenolate role where disease
relapses with attempted
steroid weaning, and
introduced relatively early
in moderate-severe
rheumatoid arthritis to
Reeves. G.E.M. Update on the immunology, diagnosis andlimit jointof damage
management systemic lupus
erythematosus. Internal Medicine Journal 2004;34:338-347.
New Treatments for systemic lupus
erythematosus
B-cell anergy
LJP 394: abetimus
B-cell depletion
Anti-CD20: rituximab
Anti-CD22: epratuzumab
Other techniques
Immunoadsorption
AntiC5a
T cell vaccination
chain transfection
Peptide therapies: edratide targeting antiDNA
idiotypes
AE Monitoring for
Muscle Psychiatric Proximal muscle weakness
Symptoms of depression,
psychosis
Eye PUD Visual changes,
Other PUD risk factors
(NSAIDs, co-morbidities)
Suggested Monitoring and Preventive-
Therapeutic Interventions for Selected GC
Adverse Effects (AE)*1
AE Monitoring for
HPA-axis suppression Symptoms of adrenal
insufficiency during
significant stress ( illness,
or surgery)
Osteoporosis BMD at baseline and q12
months thereafter if
bisphosphonates are not
given .
Osteocronosis Unexplained joint /bone
pain. (Perform MRI to
detect early GION if plain
radiography not revealing)
Suggested Monitoring and Preventive-
Therapeutic Interventions for Selected GC
Adverse Effects (AE)*2
AE Monitoring for
Cardio-vascular Lipidemia
Hypertension
Hyperglycemia Obesity
SUPPORT
CARE TREATMEN
T
MONITORIN
G
Thank You
Algorithm for the treatment of poliferattive
(class III or IV ) nephritis
Vasculitis
GR GC
X
NF B
NF B site
Hemolycte Anemia
60 mg prednisone daily
( add ) AZA (50-150 mg daily)
Leucopenia
Rarely requires any treatment
Thrombocytopenia
> 50.000 usually donate require
treatment
Life threatening thrombocytopenia
Wallace J Daniel & Hahn Hannahs Bevra : Dubois lupus Erythematosus, Seventh Edition, Lippincot Williams & Wilkins 2007
Primary Causes of Death and Their Contributing Factors in SLE
Primary Cause N (%)
Wallace J Daniel & Hahn Hannahs Bevra : Dubois lupus Erythematosus, Seventh Edition, Lippincot Williams & Wilkins 2007
Definitions for mild, moderately severe, and
severe lupus nephritis
Mild Disease
Focal proliferative nephritis (Class III) without adverese
histologic features such as CRESCENTS, fibrinoid necrosis or
high chronicity (i.e. chronicity index .3), or adverse clinical
features (normal renal function, proteinuria <3 g/day)
Boumpas T Dimitrios, Sidropoulus Prodromos, Bertsias George Bertsias, Optimum therapeutic approaches for lupus
nephritis: what therapy and for whom?, Nature publishing group, 2005
Mechanisms and Examples of Anti-Inflammatory
and Immunosuppressive Actions of GC
B. Transactivation of anti-inflammatory genes through binding of
activated GR dimers to glucocorticoid responsive elements
(GRE) on the corresponding gene promoter or enhancer
regions.
Annexin-1 (Anx1 or lipocortin-1; a phospholipase A2 inhibitor), I
B (inhibitor of NF B ), IL1 receptor antagonist (IL1Ra; inhibitor
of IL1-), MAPK phosphatase-1 (MKP1), secretory leucocyte
inhibitory protein (SLPI), neutral endopeptidase, IL10, etc.
GC GR GR GC
GRE GRE
Mechanisms and Examples of Anti-
Inflammatory and Immunosuppressive Actions
of GC
Mainly NF - B is affected, but also AP1, NFAT, and so on
with end result the transcriptional inhibition of :
Wallace J Daniel & Hahn Hannahs Bevra : Dubois lupus Erythematosus, Seventh Edition, Lippincot Williams & Wilkins 2007
Principal Immune Serologies and Their Value in SLE
Autoantibody % in SLE % in Normals
Antinuclear 98 5-10
Anti-DNA 50 <1
Anti-Sm 25 <1
Anti RNP 25 <1
Antiphospholipid 33 5
Anti-Ro/SSA 20 <1
Anti-La/SSB 15 <1
Antineuronal 20 <1
Antiribosomal P 20 <1
Low serum complement 50 5
MCTD, mixed connective tissue disease
Wallace J Daniel & Hahn Hannahs Bevra : Dubois lupus Erythematosus, Seventh Edition, Lippincot Williams & Wilkins 2007
Definitions for mild, moderately severe, and
severe lupus nephritis
Moderate disease
Nephrotic range proteinuria with normal renal function
Severe disease
Nephrotic range proteinuria in combination with impaired
renal function (at least 30% increase in serum creatinine)
Boumpas T Dimitrios, Sidropoulus Prodromos, Bertsias George Bertsias, Optimum therapeutic approaches for lupus
nephritis: what therapy and for whom?, Nature publishing group, 2005
Relative Biologic Potency and
Pharmacokinetics of selected Glucocorticoids
(GC)
Genomic Mineralc Biologic Half
Half-Life
GC Anti- orticoid Life
(Minutes)
inflammatory Activity (Hours)
Cortisol 20 1 60 8-12
Cortisone 25 0.8 60 8-12
Prednisone 5 0.8 180 12-36
Prednisolone 5 0.8 180 12-36
Methylprednisolone 4 0.5 180 12-36
Triamcinolone 4 0 180 12-36
Dexamethasone 0.75 0 220 36-72
Steps in Pathogenesis of SLE
1. Genetic factors/immune dysfunction
2. Environmental/endogenous trigger
3. Inflammation
4. Development of Autoimmune
5. Accelerated of Antigen
6. Tissue Damage
7. Clinical Disease
Potential involvement of the innate immune system in atherogenesis.
Different molecules belonging to the innate system can be involved
in the process of atherogenesis. Petraxines, patterns-recognation
receptors, and different cytokine have been shown to induce some
pro-atherogenic phenomenon.
Urticaria
Papulonodular mucinosis
Anetoderma/cutis laxa
Acanthosis nigricans
Erythema multiforme
Leg ulcers
Lichen Planus
Severe Disease
Moderately severe as defined above but not
remitting after 6-12 months of therapy, or
Chronic lesions
Glomerular sclerosis (segmental, global)
Fibrous adhesions
Fibrous crescents
Lau Sing Chak, Atlas of Lupus Erythematosus 2007
New Treatments for systemic lupus
erythematosus
Anticytokine therapies
AntiTNF
Anti-interleukin-1-receptor:anakinra
Anti-interleukin 10
Anti-interleukin 6 receptor
Anti-interferon alpha
Anti B-lympocyte stimulator (Blys)
Costimulation inhibition
AntiCD154
CTA4lg: abatacept